Loading
Heart Failure Treatment and Management / Diabetes Treatment and Management · Journal article
Journal of the American College of Cardiology · August 1, 2026
Well-designed and adequately powered for the question it asks.
In a prospective RCT of 706 people with diabetes and HF risk factors, natriuretic peptide-based screening identified HF in 24.6% vs 1% with usual care (OR 58, 95% CI 14–236, P<0.001) over 6 months, with a number needed to screen of 5. Most cases were HF with preserved ejection fraction, and screening was associated with increased SGLT2 inhibitor use (24% to 39%), but clinical outcomes beyond diagnosis and health status were not reported.
Prospective, multicenter, unblinded, randomized controlled trial. Community-based participants aged ≥40 years with type 1 or type 2 diabetes (90% type 2) and at least 1 additional HF risk factor, but without known HF, recruited in west of Scotland. Median age 71 years, 69% male, median diabetes duration 12.5 years, 26% with 2 HF risk factors and 10% with ≥3 risk…. Intervention: N-terminal pro-B-type natriuretic peptide screening with echocardiography if biomarker ≥125 pg/mL. Compared with: Usual care. n = 706. West of Scotland.
HF diagnosed in 87 of 354 (24.6%) in screening group vs 2 of 352 (1%) in usual care Odds ratio 58 (95% CI 14–236, P<0.001) for HF detection with screening vs usual care Number needed to screen was 5 (95% CI 4–6)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Screening with natriuretic peptides identifies a substantial burden of unrecognized symptomatic HF in high-risk people with diabetes, enabling initiation of disease-modifying therapy. However, the absence of reported HF hospitalizations, mortality, or symptom outcomes over 6 months limits ability to assess clinical benefit of earlier identification.
Well-designed RCT with clear primary endpoint showing natriuretic peptide screening identifies unrecognized HF in diabetes at high frequency with robust effect size, though clinical outcomes and longer-term follow-up remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Screening with natriuretic peptides identifies a substantial burden of unrecognized symptomatic HF in high-risk people with diabetes, enabling initiation of disease-modifying therapy. However, the absence of reported HF hospitalizations, mortality, or symptom outcomes over 6 months limits ability to assess clinical benefit of earlier identification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Heart failure (HF) is a common cardiovascular complication of diabetes. Early identification of unrecognized HF enables initiation of disease-modifying therapies. International diabetes and HF clinical practice guidelines are inconsistent with respect to recommendations for screening for HF in people with diabetes. OBJECTIVES: The purpose of this trial was to evaluate the diagnostic yield of a natriuretic peptide-based HF screening strategy in people with diabetes and HF risk factors. METHODS: TARTAN-HF (Targeted Assessment in high-Risk paTients with diAbetes to ideNtify undiagnosed HF) was a prospective, multicenter, unblinded, randomized controlled trial. Community-based participants aged ≥40 years with type 1 or type 2 diabetes and at least 1 additional HF risk factor, but without known HF, were recruited in the west of Scotland. Participants were randomized to N-terminal pro-B-type natriuretic peptide screening (with echocardiography if N-terminal pro-B-type natriuretic peptide ≥125 pg/mL) or usual care. The primary outcome was a HF diagnosis at 6 months. HF was defined according to 2021 European Society of Cardiology Heart Failure guidelines. Secondary and exploratory outcomes included HF phenotype, sodium-glucose cotransporter 2 inhibitor use, and a composite of HF hospitalization or death. RESULTS: From January 11, 2023 to May 29, 2025, 706 participants were randomized (354 screening; 352 usual care). Median age was 71 years, 69% were male, and 90% had type 2 diabetes. Median duration of diabetes was 12.5 years. Two HF risk factors were present in 26% and 3 or more risk factors in 10%. At 6 months, HF was diagnosed in 87 (24.6%) in the screening group vs 2 (1%) in usual care (OR: 58; 95% CI: 14-236; P < 0.001). Most cases were HF with preserved ejection fraction (23%). The number needed to screen was 5 (95% CI: 4-6). Sodium-glucose cotransporter 2 inhibitor use increased from 24% to 39% in the screening group. Patients found to have unrecognized HF had significantly impaired health status as assessed using the Kansas City Cardiomyopathy Questionnaire-12 overall summary score compared with those without HF (median: 65.6 vs 89.6). CONCLUSIONS: A HF screening strategy identified a large proportion of patients living with diabetes with unrecognized symptomatic HF (mostly HF with preserved ejection fraction). Screening strategies for HF should be further investigated and considered for adoption in the care of people with diabetes. (Targeted Assessment in high-Risk paTients with diAbetes to ideNtify undiagnosed Heart Failure: NCT05705869).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.